ONCY: Oncolytics Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Historical context for ONCY
Across the 16 sessions after earlier ONCY headlines, the stock closed higher 11 times and lower 5 times, with a median move of 2.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ONCY | SPY |
|---|---|---|---|
| Feb 24, 2026 | Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer | +6.6% | +0.7% |
| Feb 4, 2026 | Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer | +2.5% | -0.5% |
| Jan 26, 2026 | THE RESILIENCE DOCTRINE: 5 Assets Securing the 2026 Sovereign Stack | -8.9% | +0.5% |
| Jan 16, 2026 | Oncolytics Biotech® Announces Results of Special Meeting of Shareholders | +3.8% | -0.1% |
| Jan 12, 2026 | Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer | +2.5% | +0.2% |
| Jan 9, 2026 | Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada | -2.4% | +0.7% |
Quantisnow market dataNASDAQ
ONCY
Oncolytics Biotech Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for ONCY
Full ONCY profile on Quantisnow Follow ONCY and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time